Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial

Hemostemix Inc. is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular health associated with health-span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function, and immune system improvement as measured by decreased inflammation.

About Prof. Dr. Ernst von Schwarz Dr. von Schwarz brings more than three decades of cardiovascular, academic and regenerative-medicine experience to the study. Triple board certified as a transplant surgeon, cardiologist and physician-scientist at Cedars-Sinai Medical Center and UCLA, Dr. von Schwarz has published more than 150 scientific papers, including as co-author of Hemostemix' retrospective study evaluating transcatheter implantation of VesCell in patients with ischemic and non-ischemic cardiomyopathy. He joined Hemostemix' Scientific Advisory Board in 2022; and, he joined Phase II investigator Dr. York Hsiang in Hemostemix' educational webinar, When Standard Heart Treatment Isn't Enough, May 2026. Most recently, Dr. von Schwarz is the featured expert in HeartCode, a powerful and emotionally charged documentary that details how most heart-related deaths are preventable, and how longevity is achievable.

"There is an important connection between cardiovascular health and longevity: our organs cannot remain healthy without adequate circulation," said Dr. von Schwarz. "The VesCell™ data to-date supports a properly designed longevity study, to measure whether cardiovascular function, physical capacity, quality of life and other objective markers of health-span can be preserved and improved; and, I look forward to answer these questions rigorously," he said.

From Restoring Circulation to Extending Health-span: Longevity The Longevity trial is designed to generate clinical evidence that support participation in health-span competitions, some which offer up to US$101 million in prize funding to accelerate innovations that improve healthy human aging. One such competition measures longevity as increases in muscle capacity as defined by the 6 minute walk test, improved cognition and immune system function, which Hemostemix' clinical results mirror. For example, in the study co-authored by Dr. von Schwarz, subjects with a left ventricle ejection fraction below 20% improved from a mean LVEF of 14.6% before treatment to 28.4% at final follow-up, representing a 94.5% relative improvement (p < 0.003), which is consistent with improvement in Subjects' six minute walk test.

Improved 6 Minute Walk Test and Improved Heart Function: In the Phase I Angina trial, mean six-minute walk distance increased 81.3 meters post treatment at 3 months, p<0.001 and remained as an increase of 79.6 meters at 6 months from baseline, p<0.001 (Tresukosol et al., 2006). In the same study, the proportion of heart that was suffering from inadequate blood circulation improved 45.3%: myocardial perfusion defects decreased 37.9% at three months, p<0.004, and decreased by 45.3% at six months from baseline, p<0.005 (Tresukosol et al., 2006).

Reversal of Heart Failure as Measured by NYHA Classification: The New York Heart Association (NYHA) classification grades heart failure from Class I, where normal activity causes no symptoms, to Class IV (end stage), where shortness of breathe and chest symptoms occur even at rest. In Hemostemix' 41 patient Phase I, NYHA classification decreased from Class IV/III to Class III/II at 180 days, p<0.05, reflecting substantially better daily function and fewer heart-failure symptoms (Arom et al., 2008).